Pre-Conference Workshop Day
Tuesday, December 7


Negotiating the Translation Pathways for iPSC-Derived Immune Effectors Cells & Engineered iPS Derived T Cells For Solid and Hematological Tumors
9:30am – 12pm EST

Deriving “off-the-shelf” cancer fighting immune effector cells from iPSC offers a remarkable opportunity for overcoming the limitations of current autologous CAR-T cell therapies. However as promising as the iPSC approach is, it also presents a series of different challenges.
What degree of donor-recipeint compatibility is required? There are also unique regulatory requirements, inherent differences between iPSC lines in their biological properties and capacity for lineage specific diferentiation, and propensity for onogenic mutations. Cartherics has developed a comprehensive platform for creating clinic-ready, gene-edited, CAR- iNK cells for application in solid tumor immunotherapy. We will discuss the many challenges and potential solutions for successful clinical translation.

This workshop will cover:

  • Propagation, gene editing and cloning of iPSC lines
  • Functional and safety evaluation
  • Challenges with scale up manufacture
  • Engineered iPS derived cell therapies can be designed to overcome multiple
    mechanisms of treatment failure and relapse.
  • PSC derived therapies provide a homogenous and uniform source of off the shelf cell
    therapy products.

Workshop Leader

Richard Boyd
Chris Bond

Richard Boyd
Cartherics PL

Chris Bond
SVP, preclinical and Translational Sciences
Notch Therapeutics


Utilizing HiPSCs for Development of Off-the-Shelf T-Cell Therapies for Cancer & & DMSO Free Method of Freezing iPS Cells & Cells Differentiated From iPS Cells
1:00pm – 3:30pm EST

Allogeneic or “off-the-shelf” approaches hold great promise to change the way we treat cancer patients, with universal approaches allowing us to make cell therapies accessible to many more patients. Our proprietary, stem-cell derived allogeneic technology only requires one cell line for starting material and is capable of producing functional T-cells and is applicable to a broad range of targets and modalities.

This workshop will cover:

  • The unique benefits and challenges of producing T-cells from iPSC
  • The value of leveraging clinical autologous T-cell learnings to optimize and scale iPSC T-cells
  • Considerations and challenges for scale up and leveraging GMP production of genetically edited iPSC T-cells
  • Engaging with regulatory agencies – what are their key expectations?
  • Method of developing new protocol for iPS cells
  • Compatibility of method with robotic cell culture and cell manufacturing
  • Preservation of neuronal cells differentiated from iPS cells
  • Resources to help improve your preservation practices

Workshop Leaders

Jo Brewer

Jo Brewer
Head of Allogenic Research

Helen Tayton Martin
Allison Hubel

Helen Tayton-Martin

Allison Hubel
Professor, Department of Mechanical Engineering Director, Technological Leadership Institute
University of Minnesota